Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
XSPRAY PHARMA AB (PUBL) logo — www.xspraypharma.com

XSPRAY PHARMA AB (PUBL)

www.xspraypharma.com

Founded 2003 Sweden Sweden 35 employees Post-IPO Debt Total: $100.00M Biopharma, Biotechnology +2

General Information

Company Name XSPRAY PHARMA AB (PUBL)
Founded Year 2003
Location Sweden Sweden
Employees 35
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with XSPRAY PHARMA AB (PUBL). To contact XSPRAY PHARMA AB (PUBL), visit xspraypharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does XSPRAY PHARMA AB (PUBL) compare?

A PDF of XSPRAY PHARMA AB (PUBL) and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting XSPRAY PHARMA AB (PUBL) soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About XSPRAY PHARMA AB (PUBL)

Xspray Pharma (Nasdaq Stockholm: XSPRAY) is a Swedish-based pharmaceutical company founded in 2003 with the goal of enhancing patients' quality of life through the development and production of pharmaceuticals. The company specializes in utilizing innovative, patented, and scalable technology to create improved versions of existing drugs, primarily focusing on protein kinase inhibitors (PKIs) for cancer treatment. With a strong pipeline of product candidates and the HyNap technology, Xspray Pharma aims to enter the market before secondary patents expire, ensuring rapid patient benefits. The company's first product, XS0004 dasatinib, is awaiting FDA approval and has obtained orphan drug status in the US. Xspray Pharma's management team brings extensive experience in the pharmaceutical industry. The company's shares are publicly traded on Nasdaq Stockholm, and their commitment to utilizing leading-edge technology and industry expertise places them at the forefront of the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. In November 2024, Xspray Pharma secured a kr100.00M Post-IPO Debt investment from Buntel and Fenja Capital II, showcasing strong investor confidence in the company's future prospects. For more information, visit www.xspraypharma.com.

Business keywords: Pharmaceuticals, Drug development, Innovative technology, Patented technology, Scalable technology, Clinical development, Pipeline management, Orphan drug status, Protein kinase inhibitors (PKIs), Cancer treatment, FDA approval, Management expertise, Nasdaq Stockholm listed, HyNap technology

Services & Products

Development of improved versions of protein kinase inhibitors (PKIs) for cancer treatment using innovative amorphous product development technology

Target Customers

Patients suffering from cancer and healthcare providers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt kr100.00M 2
Buntel, Fenja Capital II
06 Nov 2024
Series A Undisclosed 1
John Engelbert
05 Sep 2016

XSPRAY PHARMA AB (PUBL) Alternatives & Competitors

View All Alternatives
XSPRAY PHARMA AB (PUBL) vs
Ascelia Pharma AB
Ascelia Pharma AB Sweden

Ascelia Pharma is an oncology-dedicated orphan drug company listed on Nasdaq Stockholm under the tic...

Post-IPO Equity
16 employees
Biotechnology, Health Care
XSPRAY PHARMA AB (PUBL) vs
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals, Inc. United States

Let's transform transplant medicine. Together

Post-IPO Debt
126 employees
Biotechnology, Health Care
XSPRAY PHARMA AB (PUBL) vs
Medivir AB
Medivir AB Sweden

Improving life for cancer patients through transformative drugs

Post-IPO Equity
46 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About XSPRAY PHARMA AB (PUBL)

www.xspraypharma.com
XSPRAY PHARMA AB (PUBL) was founded in 2003.
XSPRAY PHARMA AB (PUBL) is headquartered in Sweden.
XSPRAY PHARMA AB (PUBL) operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Pharmaceuticals, Drug development, Innovative technology and Patented technology. Its customers include Patients suffering from cancer and healthcare providers.
XSPRAY PHARMA AB (PUBL) has approximately 35 employees.
XSPRAY PHARMA AB (PUBL) has completed 2 funding rounds, raising a total of $100.00M. The latest funding stage is Post-IPO Debt.
XSPRAY PHARMA AB (PUBL) offers: Development of improved versions of protein kinase inhibitors (PKIs) for cancer treatment using innovative amorphous product development technology.
Top alternatives and competitors to XSPRAY PHARMA AB (PUBL) include Ascelia Pharma AB, Veloxis Pharmaceuticals, Inc., Medivir AB, BerGenBio ASA, Pear Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
XSPRAY PHARMA AB (PUBL) and Ascelia Pharma AB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for XSPRAY PHARMA AB (PUBL), https://bouncewatch.com/company/xspray-microparticles-ab, updated 25 March 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout